Literature DB >> 23884489

A review and update on melanocyte stimulating hormone therapy: afamelanotide.

Jordan Fabrikant1, Khasha Touloei, Stuart M Brown.   

Abstract

Afamelanotide ([Nle4-D-Phe7]-alpha-MSH) is an analog of alpha-melanocyte stimulating hormone given as a subcutaneous injection. Afamelanotide is currently undergoing phase II and III trials in Europe and the US for skin diseases including vitiligo, erythropoietic protoporphyria, polymorphic light eruption and prevention of actinic keratoses in organ transplant recipients. Unregulated analogs and chemicals are being sold online ahead of formal approval. A number of counterfeit chemicals, 'Melanotans' are being sold for tanning purposes. Currently, afamelanotide is already on the market in Italy and Switzerland for patients with erythropoietic protoporphyria. This paper will review the current literature on this promising compound.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23884489

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN： 1545-9616            Impact factor:   2.114


  16 in total

Review 1.  [Erythropoietic protoporphyria : Clinical manifestations, diagnosis and new therapeutic possibilities].

Authors:  U Urbanski; J Frank; N J Neumann
Journal:  Hautarzt       Date:  2016-03       Impact factor: 0.751

Review 2.  A review of common tanning methods.

Authors:  Michael Garone; John Howard; Jordan Fabrikant
Journal:  J Clin Aesthet Dermatol       Date:  2015-02

3.  Clinical and dermoscopic changes of acquired melanocytic nevi of patients treated with afamelanotide.

Authors:  Mariachiara Arisi; M Rossi; C Rovati; C Tomasi; L Mori; L Laini; P G Calzavara-Pinton
Journal:  Photochem Photobiol Sci       Date:  2021-02-17       Impact factor: 3.982

Review 4.  Vitiligo Pathogenesis and Emerging Treatments.

Authors:  Mehdi Rashighi; John E Harris
Journal:  Dermatol Clin       Date:  2017-04       Impact factor: 3.478

Review 5.  Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders.

Authors:  Elisabeth I Minder; Jasmin Barman-Aksoezen; Xiaoye Schneider-Yin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

Review 6.  Leveraging melanocortin pathways to treat glomerular diseases.

Authors:  Rujun Gong
Journal:  Adv Chronic Kidney Dis       Date:  2014-03       Impact factor: 3.620

7.  Afamelanotide for Erythropoietic Protoporphyria.

Authors:  Janneke G Langendonk; Manisha Balwani; Karl E Anderson; Herbert L Bonkovsky; Alexander V Anstey; D Montgomery Bissell; Joseph Bloomer; Chris Edwards; Norbert J Neumann; Charles Parker; John D Phillips; Henry W Lim; Iltefat Hamzavi; Jean-Charles Deybach; Raili Kauppinen; Lesley E Rhodes; Jorge Frank; Gillian M Murphy; Francois P J Karstens; Eric J G Sijbrands; Felix W M de Rooij; Mark Lebwohl; Hetanshi Naik; Colin R Goding; J H Paul Wilson; Robert J Desnick
Journal:  N Engl J Med       Date:  2015-07-02       Impact factor: 91.245

Review 8.  MC1R, the cAMP pathway, and the response to solar UV: extending the horizon beyond pigmentation.

Authors:  Jose C García-Borrón; Zalfa Abdel-Malek; Celia Jiménez-Cervantes
Journal:  Pigment Cell Melanoma Res       Date:  2014-05-30       Impact factor: 4.693

Review 9.  Protoporphyrin IX: the Good, the Bad, and the Ugly.

Authors:  Madhav Sachar; Karl E Anderson; Xiaochao Ma
Journal:  J Pharmacol Exp Ther       Date:  2015-11-20       Impact factor: 4.030

10.  Erythropoietic protoporphyria: time to prodrome, the warning signal to exit sun exposure without pain-a patient-reported outcome efficacy measure.

Authors:  D Wensink; J G Langendonk; J R Overbey; M Balwani; E J E Van Broekhoven; M A E M Wagenmakers; J H P Wilson; K Wheeden; H Naik; R J Desnick
Journal:  Genet Med       Date:  2021-05-03       Impact factor: 8.822
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.